Japan is going ahead and implementing an “off-year” drug reimbursement price cut for fiscal 2025 (which starts 1 April) despite opposition from the local pharmaceutical industry.
A 25 December announcement from the Ministry of Health, Labour and Welfare (MHLW) indicated the broad re-pricing under the country’s National Health Insurance (NHI) scheme aims to save JPY246.6bn ($1.57bn) in overall drug spending and JPY64
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?